Glaukos Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Good afternoon. I should say this is Marissa Bych with Morgan Stanley Equity Research. I work with David Lewis covering med tech. I'm very excited this afternoon to have with me Glaukos Corporation. I think this is their first time presenting at our Morgan Stanley Healthcare Conference. So welcome. It's great to have you. And I'm here with Joe Gilliam, the CFO and SVP of Corporate Development; and also Chris Calcaterra, the COO. So looking forward to an exciting conversation over the next 30 minutes.
Questions & Answers
Joe or maybe Chris, I wanted to start off with kind of the here and now dynamics of COVID-19 and then we can work into what you see for Glaukos longer term and maybe some comments on Avedro as well. But for now, I was hoping that we can talk about how things have trended since the second quarter since your report. Obviously, iStent sales were down roughly 50% year-over-year in the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |